NCT03113461 (MCI:OSA) is a NA clinical trial of CPAP in Mild Cognitive Impairment, sponsored by University of Pennsylvania.

Who is sponsoring NCT03113461?

NCT03113461 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT03113461?

Interventions in NCT03113461: CPAP.

What condition does NCT03113461 study?

NCT03113461 studies Mild Cognitive Impairment, Sleep Apnea, Obstructive.

Is NCT03113461 still recruiting?

NCT03113461 is currently active, enrolled. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT03113461: MCI:OSA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MCI: CPAP Treatment of OSA (Memories2)

Active, enrolled NA Last updated 12 April 2023

What this trial tests

NA trial testing CPAP in Mild Cognitive Impairment in 327 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 January 2018

Primary endpoint
31 January 2023

1 July 2025

Quick facts

Lead sponsor	University of Pennsylvania
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	327
Start date	19 January 2018
Primary completion	31 January 2023
Estimated completion	1 July 2025
Sites	4 locations across United States

Drugs / interventions tested

CPAP

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sleep Apnea, Obstructive — all drugs for Sleep Apnea, Obstructive →

Sponsor

University of Pennsylvania

Who can join

Adults 55 to 85, any sex, with Mild Cognitive Impairment or Sleep Apnea, Obstructive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this project is to determine whether obstructive sleep apnea (OSA) treatment with positive airway pressure therapy (CPAP) can delay the progression of cognitive impairment in patients with amnestic Mild Cognitive Impairment (MCI) as measured by cognitive testing, and brain magnetic resonance imaging (MRI) scans. Study participants will be assessed at baseline, six-month (cognitive tests only) and one-year follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Predictors of Adherence to Continuous Positive Airway Pressure in Older Adults With Apnea and Amnestic Mild Cognitive Impairment.
Richards KC, Lozano AJ, Morris J, Moelter ST, et al · · 2023 · cited 6× · PMID 37021413 · DOI 10.1093/gerona/glad099

Verify or expand the search:

Other trials of CPAP

Trials testing the same drug.

NCT07417111 — Continued Pressure for Alveolar Protection (CPAP Trial) · NA · not yet recruiting
NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07504926 — A Randomised Feasibility Study of CPAP in Large Airway Collapse · NA · not yet recruiting
NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03113461 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03113461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing